Abstract
The increasing prevalence of obesity has significant implications for healthcare, more particularly since it is a major risk factor for type 2 diabetes and cardiovascular diseases. However, not every obese patient is at the same risk of developing future metabolic and cardiovascular complications. Therefore, there is an urgent need for novel biomarkers for early identification of obese patients at high risk. Possible candidate biomarkers are microRNAs, which are highly conserved non-coding RNA molecules of approximately 22 nucleotides that exert post-transcriptional effects on gene expression. They are expressed in a tissue- and cell-type specific manner, play essential roles in many biological and pathological processes and are released in human peripheral blood in a disease-specific manner where they remain stable due to association with lipoprotein and phospholipids. All these characteristics suggest that they are putative diagnostic biomarkers. This review summarizes microRNAs with a functional role in the pathogenesis of atherosclerosis, myocardial infarction, ischemia/reperfusion injury and cardiac remodeling. It emphasizes those which have already been deregulated in association with obesity-related risk factors clustered in the metabolic syndrome. It demonstrates that several microRNAs which have been claimed to be biomarkers for cardiovascular diseases have already been deregulated in association with metabolic disorders prior to cardiovascular diseases. Finally, it summarizes which of these functionally validated microRNAs are deregulated in the circulation making them easily accessible for detection and thus into candidate biomarkers for early diagnosis of obesity-induced cardiovascular events.
Keywords: microRNA, atherosclerosis, cardiovascular diseases, obesity, metabolic syndrome, biomarker.
Current Pharmaceutical Design
Title:MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Volume: 19 Issue: 32
Author(s): Maarten Hulsmans and Paul Holvoet
Affiliation:
Keywords: microRNA, atherosclerosis, cardiovascular diseases, obesity, metabolic syndrome, biomarker.
Abstract: The increasing prevalence of obesity has significant implications for healthcare, more particularly since it is a major risk factor for type 2 diabetes and cardiovascular diseases. However, not every obese patient is at the same risk of developing future metabolic and cardiovascular complications. Therefore, there is an urgent need for novel biomarkers for early identification of obese patients at high risk. Possible candidate biomarkers are microRNAs, which are highly conserved non-coding RNA molecules of approximately 22 nucleotides that exert post-transcriptional effects on gene expression. They are expressed in a tissue- and cell-type specific manner, play essential roles in many biological and pathological processes and are released in human peripheral blood in a disease-specific manner where they remain stable due to association with lipoprotein and phospholipids. All these characteristics suggest that they are putative diagnostic biomarkers. This review summarizes microRNAs with a functional role in the pathogenesis of atherosclerosis, myocardial infarction, ischemia/reperfusion injury and cardiac remodeling. It emphasizes those which have already been deregulated in association with obesity-related risk factors clustered in the metabolic syndrome. It demonstrates that several microRNAs which have been claimed to be biomarkers for cardiovascular diseases have already been deregulated in association with metabolic disorders prior to cardiovascular diseases. Finally, it summarizes which of these functionally validated microRNAs are deregulated in the circulation making them easily accessible for detection and thus into candidate biomarkers for early diagnosis of obesity-induced cardiovascular events.
Export Options
About this article
Cite this article as:
Hulsmans Maarten and Holvoet Paul, MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/13816128113199990364
DOI https://dx.doi.org/10.2174/13816128113199990364 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcriptional Regulation of the Heme Oxygenase-1 Gene Via the Stress Response Element Pathway
Current Pharmaceutical Design Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Usefulness of Contrast-enhanced Ultrasound in the Evaluation of Chronic Kidney Disease
Current Medical Imaging Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus
Current Diabetes Reviews Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Heat Shock Response Regulates Insulin Sensitivity and Glucose Homeostasis: Pathophysiological Impact and Therapeutic Potential
Current Diabetes Reviews Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA <i>Panax notoginseng</i> Saponins Promote Cell Death and Chemosensitivity in Pancreatic Cancer through the Apoptosis and Autophagy Pathways
Anti-Cancer Agents in Medicinal Chemistry Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Role of the Wnt/β-Catenin Pathway in the Pathogenesis of Alcoholic Liver Disease
Current Molecular Pharmacology Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research The Multifunctional Protein C System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Novel Trends in the Treatment of Cardiovascular Disorders: Site- and Event- Selective Adenosinergic Drugs
Current Medicinal Chemistry Biological Responses to Hydrogen Molecule and its Preventive Effects on Inflammatory Diseases
Current Pharmaceutical Design Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets